Clinical trials: Oligometastases
Stage IV or Recurrent Carcinoma or Sarcoma
Definitive Therapy for Oligometastatic Solid Malignancies
Patients with metastatic cancer are usually treated with systemic therapy (treating the entire body) with the assumption that any localized treatment of clinically apparent metastases would not impact survival.
- Trial name
- NCT01898962
- Testing
- Complete Surgical Removal, Stereotactic Radiosurgery, Ablative external beam radiation dose
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Rocky Mountain Cancer Centers
Colorectal Carcinoma, Oligometastases
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Background and Significance: Colorectal cancer (CRC) ranks as the third most common cancer and the second leading cause of cancer-related deaths globally.
- Conditions
- Colorectal Carcinoma, Oligometastases, pMMR, MSS
- Trial name
- NCT06850103
- Testing
- short-course radiotherapy, CAPEOX/XELOX, Serplulimab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Oligometastatic Hormone Sensitive Prostate Cancer
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients
INDICATION: Oligometastatic hormone-sensitive prostate cancer patients. METHODOLOGY: Open label, double arm, randomized 1:1, multicenter phase III study.
- Trial name
- Oligo-PRESTO (NCT04115007)
- Testing
- Stereotactic Body Radiotherapy (SBRT) + Standard of care, Standard of care
- Where
- 35 sites in France, Martinique
- Volunteers
- 550 people
- Sponsor
- UNICANCER
Breast Cancer Metastatic
Radiotherapy for Extracranial Oligometastatic Breast Cancer
More and more evidence suggests that local radiotherapy can improve the outcomes for patients with oligometastatic disease. The purpose of this study is to assess the impact of radiotherapy, compared with standard systemic…
- Trial name
- NCT04646564
- Testing
- standard of care, radiotherapy + standard of care
- Where
- 2 sites in China
- Volunteers
- 170 people
- Sponsor
- Chinese Academy of Medical Sciences
Prostate Cancer, Oligometastases
Stereotactic Body Radiation for Prostate Oligometastases
Men with oligometastatic prostate cancer lesions will be randomized (1:2) to observation versus SBRT. The study will NOT be blinded. Within three weeks of the initial treatment planning, SBRT (1-5 fractions) will be administered.
- Trial name
- ORIOLE (NCT02680587)
- Testing
- SBRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nasopharyngeal Carcinoma, Neoplasm Metastasis
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
This single-center, open-label, randomized phase II trial evaluates whether CT-guided local ablation of liver and/or lung oligometastases, added to systemic therapy, improves the objective response rate compared with systemic…
- Conditions
- Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases, Liver Metastases
- Trial name
- NCT07824856
- Testing
- CT-guided percutaneous local ablation, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Low-dose Radiotherapy, Tumor Microenvironment
Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy
The purpose of this phase Ⅱ trial was to investigate the effect of low-dose radiotherapy (LDRT) on the tumor immune microenvironment (TME) in oligometastasis, oligoprogression, and oligopersistence of non-small cell lung cancer…
- Conditions
- Low-dose Radiotherapy, Tumor Microenvironment, Non-Small Cell Lung Cancer
- Trial name
- NCT06331585
- Testing
- low dose radiotherapy
- Where
- China
- Sponsor
- Hetian District People's Hospital
Prostate Cancer
Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer
Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer.
- Trial name
- Bullseye (NCT04443062)
- Testing
- 177Lu-PSMA-617
- Where
- 4 sites in Cyprus, Netherlands
- Volunteers
- 58 people
- Sponsor
- Radboud University Medical Center
Breast Cancer, Oligometastasis
Metastasis-directed Therapy for Oligometastases of Breast Cancer
OLIGAMI trial is a multi-institutional, two-arm, open-label, randomized controlled phase III trial being conducted with the participation of 50 hospitals belonging to Japan Clinical Oncology Group.
- Conditions
- Breast Cancer, Oligometastasis, Metastatic Breast Cancer
- Trial name
- OLIGAMI (NCT06135714)
- Testing
- Systemic therapy for 12 weeks after primary registration, Radiation therapy (SBRT/conventional RT), Surgery
- Where
- Japan
- Volunteers
- 146 people
- Sponsor
- Tokyo Medical and Dental University
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
This single-center, prospective, single-arm Phase II clinical trial is designed to evaluate the efficacy and safety of combining hepatic artery infusion chemotherapy (HAIC, for up to 4 cycles) with iparomlimab/tuvonralimab plus…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy
- Trial name
- NCT07062055
- Testing
- Anti-VEGF, Immunotherapy, Local Therapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shandong Cancer Hospital and Institute
Oligometastatic Disease, Non-small Cell Lung Cancer
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
A Phase II randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic Non-small cell lung cancer patients.
- Conditions
- Oligometastatic Disease, Non-small Cell Lung Cancer, Driver Mutation
- Trial name
- TARGET-01 (NCT05277844)
- Testing
- Local Consolidative Radiation Therapy, TKI
- Where
- India
- Volunteers
- 106 people
- Sponsor
- Tata Memorial Hospital
Non-Small-Cell Lung Cancer
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC
This is a phase II clinical trial of SHR-1210 （an anti-PD-1 Inhibitor） simultaneously combined with hypofraction radiotherapy in patients with previously treated oligometastatic NSCLC.
- Trial name
- NCT03557411
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shandong Cancer Hospital and Institute
Metastatic Tumor
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
This study is a phase III multi-institutional randomized trial. Patients will be randomized in a 1:2 ratio between current standard of care treatment (Arm 1) vs.
- Trial name
- SABR-SYNC (NCT05717166)
- Testing
- Palliative Radiotherapy, Chemotherapy, Hormone therapy
- Where
- 5 sites in Canada, Switzerland
- Volunteers
- 180 people
- Sponsor
- David Palma
Oligometastatic Prostate Cancer
Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer
This study aims to probe the effect of SBRT as a treatment oligometastases of prostate cancer, regardless of basal treatment received, and I know the response, biochemical control, the progression-free survival as well as their…
- Trial name
- NCT02192788
- Testing
- Stereotactic Body Radiation Therapy for Oligometastases
- Where
- 22 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Grupo de Investigación Clínica en Oncología Radioterapia
Ovarian Cancer Recurrent
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
SOPRANO is a multi-centre phase II trial designed to assess the impact of SBRT with or without continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and…
- Trial name
- SOPRANO (NCT05990192)
- Testing
- Niraparib oral capsule, SBRT
- Where
- 7 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Non Small Cell Lung Cancer
A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases
An observational study to explore prognoses and clinical treatments of the patients with non-small cell lung cancer complicated with oligometastases
- Trial name
- NCT03427541
- Testing
- Surgeries
- Where
- 10 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Tang-Du Hospital
Prostate Cancer, Breast Cancer
Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases
Metastatic spread of cancer from its primary site to distant organs is the commonest cause of death from cancer. The term oligometastases describes an intermediate metastatic state, in which cancer exists as a limited number of…
- Conditions
- Prostate Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- CORE (NCT02759783)
- Testing
- SBRT, Standard of Care
- Where
- 30 sites in Australia, United Kingdom
- Volunteers
- 245 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Oligometastases
Stereotactic Body Radiation With Nelfinavir for Oligometastases
Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered.
- Trial name
- NCT01728779
- Testing
- Nelfinavir, Stereotactic Body Radiation (SBRT)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Liver Metastases, Colorectal Cancer
Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer
The role of radiotherapy in metastatic cancer has historically been limited to palliation while metastasectomy or radiofrequency has emerged as playing a major role in disease control.
- Trial name
- OLIVER (NCT03532204)
- Testing
- SBRT, Chemotherapy
- Sponsor
- UNICANCER
Oligometastases of the Spine
Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine
In light of the increasing experience with magnetic resonance image-guided radiotherapy (MRgRT) and adaptive planning and advances in magnetic resonance (MR)-only planning, the investigators propose here to evaluate the…
- Trial name
- NCT03878485
- Testing
- MRIdian Linac System from ViewRay, Stereotactic MRI-guided Adaptive Radiotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine